References
- Kay N E, Shanafelt T D, Call T G, Wu W, LaPlant B R. N9986: a phase II trial of ßthalidomide in patients with relapsed chronic lymphocytic leukemia. Leuk Lymphoma 2009; 50: 588–592
- Bartlett J B, Dredge K, Dalgleish A G. The evolution of thalidomide and its IMiD derivatives as anticancer agents. Nat Rev Cancer 2004; 4: 314–322
- Kay N E. The angiogenic status of B-CLL B cells: role of the VEGF receptors. Leuk Res 2004; 28: 221–222
- Chanan-Khan A, Miller K C, Takeshita K, Koryzna A, Donohue K, Bernstein Z P, et al. Results of a phase 1 clinical trial of thalidomide in combination with fludarabine as initial therapy for patients with treatment-requiring chronic lymphocytic leukemia (CLL). Blood 2005; 106: 3348–3352
- Chanan-Khan A, Porter C W. Immunomodulating drugs for chronic lymphocytic leukaemia. Lancet Oncol 2006; 7: 480–488
- Ferrajoli A, Lee B N, Schlette E J, O'Brien S M, Gao H, Wen S, et al. Lenalidomide induces complete and partial remissions in patients with relapsed and refractory chronic lymphocytic leukemia. Blood 2008; 111: 5291–5297
- Chanan-Khan A, Miller K C, Musial L, Lawrence D, Padmanabhan S, Takeshita K, et al. Clinical efficacy of lenalidomide in patients with relapsed or refractory chronic lymphocytic leukemia: results of a phase II study. J Clin Oncol 2006; 24: 5343–5349